Bone morbidity in chronic myeloproliferative neoplasms

Area of Science:

• Hematology
• Oncology
• Bone Metabolism

Background:

• Philadelphia chromosome-negative chronic myeloproliferative neoplasms (MPN) like essential thrombocythemia, polycythemia vera, and primary myelofibrosis are linked to comorbidities.
• Cardiovascular diseases, thrombotic events, and an increased risk of osteoporotic fractures are common in MPN patients.
• The prevalence, underlying mechanisms, and therapeutic strategies for bone disease in MPN are not well-established.

Purpose of the Study:

• To review current knowledge on the association between bone disease and chronic myeloproliferative neoplasms.
• To explore potential mechanisms linking MPN to skeletal complications.
• To highlight the need for further research into therapeutic implications.

Main Methods:

• Literature review summarizing existing studies on MPN and bone disease.
• Discussion of proposed mechanisms, including chronic inflammation and mast cell mediator effects.
• Analysis of prevalence, risk factors, and potential treatment strategies.

Main Results:

• Chronic inflammation is implicated in the development and progression of MPN.
• Bone density loss and increased fracture risk are observed in chronic systemic inflammatory diseases.
• While mechanisms are known for systemic mastocytosis (SM), they are unclear for other MPNs.

Conclusions:

• A significant association exists between chronic myeloproliferative neoplasms and bone disease, including increased fracture risk.
• Chronic inflammation may play a role, similar to other systemic inflammatory conditions.
• Further research is crucial to elucidate specific mechanisms and develop targeted therapies for bone complications in MPN.